Apellis Pharmaceuticals Net Income 2016-2021 | APLS

Apellis Pharmaceuticals net income from 2016 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Apellis Pharmaceuticals Annual Net Income
(Millions of US $)
2020 $-345
2019 $-305
2018 $-128
2017 $-51
2016 $-27
2015 $-47
Apellis Pharmaceuticals Quarterly Net Income
(Millions of US $)
2021-06-30 $-219
2021-03-31 $-184
2020-12-31 $78
2020-09-30 $-136
2020-06-30 $-119
2020-03-31 $-169
2019-12-31 $-113
2019-09-30 $-70
2019-06-30 $-71
2019-03-31 $-51
2018-12-31 $-37
2018-09-30 $-36
2018-06-30 $-33
2018-03-31 $-22
2017-12-31 $-18
2017-09-30 $-12
2017-06-30 $-12
2017-03-31 $-9
2016-12-31
2016-09-30 $-7
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.013B $0.251B
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00